Survival gains in myelodysplastic syndromes following a decade of the modern treatment paradigm

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors appreciate the support and guidance of investigators from the Study Design and Molecular Epidemiology Core of the Vermont Center for Cardiovascular and Brain Health, funded by grant P20 GM135007 from the National Institute of General Medical Sciences, National Institutes of Health.

Ethical approval

This study was exempted by the University of Vermont’s Institutional Review Board as research not involving human subjects under 45 CFR 46.102(f).

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings in this work are openly available from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute (NCI). Access can be obtained from https://seer.cancer.gov/, using the SEER*Stat Software [13].

Additional information

Funding

Financial support for this work was received from the Northern New England Clinical Oncology Society (NNECOS) Collaborative Research Grant [0443-038501].